Popular Articles

Also In Global Health News: Text Messages To Fight Polio; TB At Pakistani Relief Camps; ARV Supply In Uganda
UNICEF Using SMS Text Messages To Fight Polio In Zambia
diet pills
Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect On Photoreceptors
Neurotech Pharmaceuticals, Inc. announced that the Company"s product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.
News of the day
Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced that it has enrolled 50% of the total projected enrollment required for its Phase IIa trial to evaluate the safety and preliminary efficacy of Serdaxin™ as a central nervous system based treatment for Major Depressive Disorder (MDD). The complete trial calls for the enrollment of up to 80 patients at multiple clinical trial sites in the United States.
Sexual Health

Louisiana House Approves Bill Allowing Providers To Refuse Certain Reproductive Health Services

The Louisiana House on Tuesday voted 82-13 to approve legislation (HB 517) that would allow some health professionals to refuse to provide certain medical services that they object to on religious or moral grounds, the New Orleans Times-Picayune reports.The House-passed bill is an amended version of a measure, introduced by Rep. Bernard LeBas (D), that a House committee rejected earlier this month. The revised bill narrowed the list of procedures that can be denied, and it applies to health providers only in public facilities, not religious health facilities statewide as in the original bill. Under the bill, public health care employees would be allowed to decline to provide abortions or abortifacient drugs. They also would be allowed to refuse participation in embryonic stem cell research or cloning, euthanasia and physician-assisted suicide. Public employees would be immune from civil lawsuits and have job security under the measure.According to the Times-Picayune, Gov. Bobby Jindal"s (R) administration backed the original bill in committee, although state Health Secretary Alan Levine indicated that the bill"s original provisions were too broad. Under the original measure, health care providers would have been allowed to refuse services such as artificial insemination, sterilization, artificial reproductive technologies and "dispensation of drugs affecting the reproductive process." The original measure also would have covered both public and private health care providers (Barrow, New Orleans Times-Picayune, 5/20).Prior to passage, the House approved an amendment to narrow the scope of the bill offered by Rep. John Bel Edwards (D), who said that the original bill"s provisions were not specific enough and could pose problems for private businesses. He also said that the original bill would have posed barriers to patients seeking access to basic treatments and medications (AP/New Orleans Times-Picayune, 5/19). The measure now advances to the state Senate for debate (New Orleans Times-Picayune, 5/20). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):